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Abstract
Most acute infections with RNA viruses are transient and subsequently cleared from the host. Recent evidence, however,
suggests that the RNA virus, West Nile virus (WNV), not only causes acute disease, but can persist long term in humans and
animal models. Our goal in this study was to develop a mouse model of WNV persistence. We inoculated
immunocompetent mice subcutaneously (s.c.) with WNV and examined their tissues for infectious virus and WNV RNA
for 16 months (mo) post-inoculation (p.i.). Infectious WNV persisted for 1 mo p.i. in all mice and for 4 mo p.i. in 12% of mice,
and WNV RNA persisted for up to 6 mo p.i. in 12% of mice. The frequency of persistence was tissue dependent and was in
the following order: skin, spinal cord, brain, lymphoid tissues, kidney, and heart. Viral persistence occurred in the face of a
robust antibody response and in the presence of inflammation in the brain. Furthermore, persistence in the central nervous
system (CNS) and encephalitis were observed even in mice with subclinical infections. Mice were treated at 1 mo p.i. with
cyclophosphamide, and active viral replication resulted, suggesting that lymphocytes are functional during viral persistence.
In summary, WNV persisted in the CNS and periphery of mice for up to 6 mo p.i. in mice with subclinical infections. These
results have implications for WNV-infected humans. In particular, immunosuppressed patients, organ transplantation, and
long term sequelae may be impacted by WNV persistence.
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Introduction
West Nile virus (WNV), a member of the Japanese encephalitis
virus serogroup in the flavivirus genus of the family Flaviviridae,
quickly spread across North America after its emergence in New
York City in 1999 [1,2]. In humans, WNV causes fever in
approximately 20% of infections and neuroinvasive disease in
,1% of infections [3,4]. In the United States from 1999 through
2007, there were over 11,000 human cases of West Nile
neuroinvasive disease and an estimate of over 1.5 million humans
infected with WNV [5]. In addition, long term sequelae, including
weakness, fatigue, and cognitive deficits, are observed in patients
with both West Nile fever and West Nile neuroinvasive disease for
up to 18 months after disease onset [6–18]. These sequelae are
likely due to the initial damage caused by the virus, but viral
persistence may also contribute to the extended recovery.
Members of the family Flaviviridae cause chronic infections,
including hepatitis C virus and pestiviruses; however, members of
the flavivirus genus are generally considered to cause acute
infections. On the other hand, there is mounting evidence that
these acute flavivirus infections can result in viral persistence. In
convalescing humans, WNV RNA persists in the urine of patients
for up to 6.7 years after disease onset [19]. In WNV-positive blood
donors, WNV RNA is detected in blood for up to 104 days after
index donation [20]. Other studies have examined the long term
persistence of virus-specific immunoglobulin M (IgM), which is
suggestive of viral persistence. Patients with West Nile disease and
WNV-positive blood donors have persistent serum IgM for up to
11 to 16 months [20–23]. In addition, IgM persists in
cerebrospinal fluid of patients with West Nile encephalitis for up
to 5 months [24] and Japanese encephalitis for up to 6 months
[25,26], suggesting that flaviviruses can persist in the CNS of
convalescing patients. In summary, these studies demonstrate that
WNV persists in the periphery and possibly in the CNS of
immunocompetent humans.
Flaviviruses and other arboviruses also persist in animal models
(reviewed in [27]). WNV persists in experimentally inoculated
animals, including macaques [28], hamsters [29], and house
sparrows [30], for up to two to six months after inoculation. The
goal of this study was to examine the persistence of WNV in
immunocompetent mice with subclinical and clinical WNV
infections. WNV persisted in the CNS and periphery of
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RNA for up to 6 mo p.i.. This persistence occurred in mice with
and without disease during the acute infection; therefore, West
Nile disease was not required for viral persistence in the brain or
spinal cord of mice. Viral persistence occurred in the face of a
robust humoral response with WNV-specific antibodies persisting
for at least 16 months. In addition, histologic lesions were observed
in the brains of mice for up to 4 mo p.i., correlating with the
presence of WNV RNA. Finally, transient immunosuppression
with cyclophosphamide resulted in WNV recrudescence, suggest-
ing that during viral persistence, the host’s immune response
prevents viral replication.
Results
WNV persists in mice
We previously showed that B6 mice are partially resistant to
West Nile disease with approximately 30% morbidity and 20%
mortality, and this resistance is not due to lack of neuroinvasion
since WNV invades the CNS of all mice by 3 days p.i. [31].
Furthermore, infectious WNV was found in the CNS and skin of
B6 mice for at least 14 days p.i. with mean viral titers of 10
3.9 and
10
4.4 PFU/g in the cerebral cortex and skin, respectively (Brown
et al., unpublished data). These high viral loads late in infection led
us to hypothesize that WNV persists in mice even without the
development of disease. Thus, we conducted a study to test this
hypothesis and to determine in which tissues and for how long
WNV persists.
We examined persistence of WNV as infectious virus and RNA
for 16 mo p.i., using our B6 mouse model. For this study, 82 mice
were inoculated s.c. with WNV and assessed for clinical disease.
Similar to previous results, the B6 mice exhibited 29% morbidity
and 22% mortality. Mice were sacrificed at 1, 2, 3, 4, 6, 9 and 16
mo p.i., and we harvested tissues that are known targets for WNV
[31], including skin, brain, spinal cord, lymph nodes, spleen,
kidney, and heart. We used several methods to improve the
sensitivity of our virus isolation (Figure S1). First, we used a co-
culturing technique, which cultured the primary cells from the
mouse tissues onto the highly susceptible Vero cell line. This
technique amplified any virus that was produced from infected
cells in the tissues. In addition, we ‘‘blind’’ passed the cultures two
more times to further amplify any infectious virus. Finally, we
tested all cell culture supernatants from the ‘‘third pass’’ even if no
cytopathic effect (CPE) was observed, which allowed us to detect
any non-cytopathic or slow growing virus. In two instances, WNV
RNA was detected in the cell culture supernatant, and cytopathic
WNV was isolated on a fourth pass (Table 1).
Using these sensitive techniques, we were able to isolate
infectious WNV from at least one tissue in all mice at 1 mo p.i.
(Table 1). Infectious WNV was most frequently isolated from the
skin at the inoculation site with 88% of eight mice positive. WNV
was isolated from all other tissues in at least one mouse (12 to
25%). After 1 mo p.i., infectious WNV was isolated in only one
mouse, which was sacrificed at 4 mo p.i. (Table 2). Virus was
isolated from three tissues of this mouse, the spinal cord, brain and
spleen. This mouse had not been sick during the acute phase of
disease (7 to 14 days p.i.), but it did show abnormal behavior for
several weeks prior to sacrifice, including repetitive motions and
over-grooming. It is unknown whether these behavioral abnor-
malities were associated with persistence of WNV; however,
meningitis was observed on histopathology, suggesting that
histologic lesions may contribute to neurologic sequelae.
WNV RNA was detected in all mice and in seven different
tissues at 1 mo p.i. although the frequencies and levels of WNV
RNA varied for the different tissues (Table 1 and Figure 1). All
samples of the skin at the inoculation site, spinal cord, brain and
spleen were positive for WNV RNA, and the other tissues ranged
from no positive samples (heart) to 75% (6/8) positive (lymph
nodes) at 1 mo p.i. (Table 1). The highest WNV RNA levels were
found in the skin at the inoculation site, spinal cord, and brain with
geometric means of approximately 1000, 5000, and 1000 WNV
copies/mg GAPDH RNA, respectively, at 1 mo p.i. (Figure 1A,
Table 1. Infectious virus and WNV RNA were isolated from at least one tissue in all mice at 1 mo p.i..
Infectious Virus (WNV RNA) in tissue
Mouse ID Inoculum Skin–inoculation site
1 Skin–distal sites
2 Spinal Cord Brain Lymph nodes
3 Spleen Kidney Heart
7 Mock 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2)
57 WNV + (+) 2 (+) + (+) 2 (+) 2 (+) 2 (+) 2 (+) 2 (2)
58 WNV + (+) 2 (2) 2 (+) 2 (+) 2 (+) 2 (+) 2 (2) 2 (2)
59 WNV + (+) 2 (+) 2 (+) 2 (+) 2 (+) 2 (+) 2 (+) 2 (2)
60 WNV + (+) + (+) 2 (+) 2 (+) 2 (2) 2 (+) 2 (2) 2 (2)
63 WNV 2 (+) 2 (2) 2 (+) + (+) 2 (+) 2 (+) 2 (2) 2 (2)
65 WNV + (+) +
4 (2) 2 (+) 2 (+) 2 (+) 2 (+) 2 (2) 2 (2)
67 WNV + (+) 2 (2) + (+) 2 (+) 2 (2) 2 (+) 2 (2) 2 (2)
90 WNV + (+) 2 (+) 2 (+) 2 (+) + (+) +
4 (+) + (+) + (2)
2 negative, + positive.
1Skin at the inoculation site consisted of the left rear footpad.
2Distal skin sites consisted of right rear footpad and both front footpads.
3Lymph nodes consisted of both popliteal and both inguinal lymph nodes.
4WNV was isolated on fourth pass.
Adult, female B6 mice were inoculated s.c. in the left rear footpad with diluent alone (mock) or with 10
3 PFU of WNV. Mice were sacrificed at 1 mo p.i., and WNV
infection was confirmed in all WNV-inoculated mice by seroconversion. Eight tissues per mouse were harvested for virus isolation and RT-PCR for WNV. Virus isolation
was performed on eight tissues per mouse by co-culturing the homogenized tissues on Vero cell monolayers. All samples were passed at least two more times onto
fresh monolayers, and tissue culture supernatants from the third passage were tested for the presence of WNV by RT-PCR. Mouse #90 was sick during acute phase of
disease (7 to 14 days p.i.). All other mice did not show any clinical disease.
doi:10.1371/journal.pone.0010649.t001
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RNA (mean of 3 WNV copies/mg GAPDH RNA, Figure 1F),
which may explain the difficulty in isolating infectious virus from
this tissue despite the high frequency of WNV RNA present
(Table 1). At 2 mo p.i., WNV RNA was again detected in at least
one tissue of all mice (Table 2); however, the frequencies of
detection declined for skin from distal sites, brain, spleen, and
kidney (Figure 1B, 1D, 1F and 1G), and WNV RNA levels were
lower in the skin at the inoculation site and spinal cord compared
to 1 mo p.i. (Figure 1A and 1C). At 3 mo p.i., 89% of nine mice
were positive for WNV RNA in at least one tissue, and skin at the
inoculation site, spinal cord, and brain were most frequently
positive at 56% (5/9, Table 2 and Figure 1). At 4 mo p.i., only
38% of eight mice were positive for WNV RNA, which was
detected in skin at the inoculation site, spinal cord and kidney. At 6
mo p.i., only one mouse was positive for WNV RNA, which was
detected in the spinal cord, and no WNV RNA was detected after
this time. This study has been repeated three times at 1 mo p.i.
(n=8 to 10) and two times at 2 mo p.i. (n=4 to 8), and very
similar results were obtained for both virus isolation and WNV
RNA in the various tissues (data not shown).
We evaluated the correlation between WNV persistence and the
disease status of the animal during the acute phase of disease (7 to
14 days p.i.). Out of 64 surviving mice, six mice were sick during
this time, and we sacrificed one sick mouse at each time point
except for 4 mo p.i. The major reason for setting up the
experimental design in this manner was to evenly distribute sick
animals in order not to bias the results, but this design also allowed
us to examine any effect of clinical disease. At 1 mo p.i., the sick
mouse (ID #90) had five tissues positive for infectious WNV
compared to only one to two positive tissues for the mice with
subclinical infection (Table 1). At 2 mo p.i., the sick mouse had five
tissues positive for WNV RNA compared to a range of only two to
four positive tissues (mean +/2 standard deviation=3.2+/20.89)
for the mice with subclinical infection (data not shown). No
differences were observed between mice with or without disease at
later time points (data not shown). Although there was no
significant correlation between WNV persistence and the disease
status, there were more positive tissues in the sick animals at the
earlier time points.
In summary, infectious WNV was isolated for at least 1 mo p.i.
and at 4 mo p.i. in one of eight mice, and WNV RNA persisted for
up to 6 mo p.i. Persistence of infectious virus occurred most
frequently in the skin at the inoculation site. Persistence of WNV
RNA occurred most frequently in the skin at the inoculation site,
spinal cord and brain, followed by spleen, lymph nodes, kidney
and heart in that order. The highest levels of WNV RNA were
found in the skin at the inoculation site, spinal cord and brain, and
WNV RNA persisted in these tissues for three, four and six months
for the brain, skin at the inoculation site, and spinal cord,
respectively. Overall these results demonstrate that persistence of
WNV is tissue dependent, suggesting that the mechanisms and/or
efficiency of viral clearance differ for the various tissues. Finally,
the persistence of WNV was observed in mice with subclinical
infection, demonstrating that disease is not required for WNV to
persist in the CNS or peripheral tissues.
WNV-specific antibody is long-lived in mice
Previous studies have shown that the persistence of antibodies to
WNV varies in different animals–up to 14 months in humans [21],
up to 15 months in horses [32], and up to 36 months in house
sparrows [33]. Thus, we examined the longevity, quantity and
quality of the antibody response in the mice from the viral
persistent study described above, using microsphere immunoassays
(MIA) and plaque reduction neutralization tests (PRNT).
We used MIAs, which are quantitative over a very broad linear
range [34], to measure antibody levels to two WNV antigens, the
structural envelope protein (E) and the nonstructural protein 5
(NS5). Sera were tested from mice that were sacrificed and from
samples obtained by serial bleeding (9 to 64 mice at each time
point, Table S1). The antibody response to E peaked at 2 to 4 mo
p.i., and all mice remained positive for E antibody for at least 16
mo p.i. (Figure 2A). The antibody response to NS5 was highest at
the first time point tested, 1 mo p.i. (Figure 2C). The antibody
levels were evaluated from 15 mice that were serially bled over
time. For antibodies to E, all 15 mice were positive at each time
point, and the response plateaued at 2 mo p.i. (average mean
fluorescence intensity [MFI]=15,500) to 6 mo p.i. (average
MFI=14,200) and slowly declined between 9 mo p.i. (average
MFI=11,100) and 16 mo p.i. (average MFI=4,800) (Figure 2B).
In contrast, the antibody response to NS5 was more variable over
time. All 15 mice were positive for antibody to NS5 through 6 mo
p.i., but only 67% were positive at 9 mo p.i. (Figure 2D). At 13
Table 2. Summary of results for virus isolation, WNV RNA, and histopathology from mice sacrificed at various times p.i..
Time post-inoculation (No. positive/No. tested)
1 mo 2 mo 3 mo 4 mo 6 mo 9 mo 16 mo
Infectious WNV–any tissue
1 8/8 0/8 0/9 1/8 0/8 0/8 0/15
WNV RNA–any tissue
1 8/8 8/8 8/9 3/8 1/8 0/8 0/15
WNV RNA–skin 8/8 7/8 5/9 1/8 0/8 0/8 0/15
WNV RNA–spinal cord 8/8 8/8 5/9 2/8 1/8 0/8 0/15
WNV RNA–brain 8/8 1/8 5/9 0/8 0/8 0/8 0/15
Histologic lesions–brain 7/8 5/8 ND 2/8 0/8 0/8 ND
ND=not done.
1The number of mice with positive results from any of the eight tissues.
Adult, female B6 mice were inoculated s.c. in the left rear footpad with diluent alone (mock) or with 10
3 PFU of WNV. Mice were sacrificed at the indicated times p.i., and
each time point included one mock-inoculated mouse. WNV infection was confirmed in all WNV-inoculated mice by seroconversion at 1 mo p.i.. Eight tissues (brain,
spinal cord, skin–inoculation site, skin–distal sites, spleen, lymph nodes, kidney, and heart) per mouse were harvested for virus isolation and RT-PCR for WNV. Virus
isolation was performed by co-culturing the homogenized tissues on Vero cell monolayers. All samples were passed at least two more times onto fresh monolayers, and
tissue culture supernatants from the third passage were tested for the presence of WNV by RT-PCR. Brains were examined for histopathology. All tissues from mock-
inoculated mice were negative for infectious virus, WNV RNA, and histologic lesions.
doi:10.1371/journal.pone.0010649.t002
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and the average MFIs increased from 1,900 at 9 mo p.i. to 2,400
at 13 mo p.i. (P=0.03, paired t-test). These results suggest that
the response to NS5 was stimulated between 9 and 13 mo p.i.. By
16 mo p.i., there was a decline in the levels of antibody to NS5
with only 20% of the 15 mice positive and an average MFI of
190.
In addition to MIAs, we evaluated the levels of neutralizing
antibodies to assess the functional antibody response. PRNTs were
performed on sera from 8 to 15 mice per time point, which were
from different mice at each time point except for 13 and 16 mo p.i.
when the same 15 mice were tested (Table S1). Consistent with the
kinetics of antibody to E (Figure 2A), the PRNT90 titers were
highest at 2 to 4 mo p.i. with means of 1:290 to 1:370 and
maximum values of 1:640 (Figure 2E). The titers were lower at 6
and 9 mo p.i. with means of 1:110 and 1:80, respectively. The
titers rebounded at 13 mo p.i. (mean of 1:190), as was observed
with the levels of antibody to NS5 (Figure 2D), but unlike the anti-
NS5 levels, the PRNT titers were not from the same mice at 9 and
13 mo p.i., and the rise in titer at 13 months may be an artifact of
the population sampled. By 16 mo p.i., the PRNT90 titers
decreased to 1:130 with 87% of 15 mice positive. When sera were
evaluated using PRNT50 as an endpoint, all WNV-inoculated
mice were positive for neutralizing antibody at all time points (data
not shown). In summary, WNV-specific antibody persisted in mice
for at least 16 months as measured by MIA for antibody to E, and
all mice had detectable neutralizing antibody at this time. On the
other hand, levels of antibody to NS5 were more variable over the
course of the study and declined to undetectable or low levels at
the end of the study.
Histopathologic changes persist in the brain
WNV persisted in the brains of mice even without clinical
disease; therefore, we questioned whether the mice lacked
histologic lesions, which might explain the lack of disease and
viral persistence. Thus, we performed histopathology on brains
from mice sacrificed at 1, 2, 4, 6, and 9 mo p.i. (n=8 per time
point). Encephalitis and/or meningitis were observed in 88%,
62%, and 25% of the mice at 1, 2 and 4 mo p.i., respectively, and
no lesions were observed at 6 or 9 mo p.i. (Table 2). In addition,
the decline in histologic lesions in the brain at 4 to 6 mo p.i.
correlated with the decline in WNV RNA (Table 2) and the
decline in neutralizing antibody (Figure 2E). Representative
examples of histologic lesions are shown in Figure 3. The
encephalitis was characterized by foci of gliosis, neuronal loss,
prominent vessels, and lymphoid perivascular cuffing (Figure 3A
and 3C). The meningitis was characterized by focal lymphocytic
and lymphoplasmacytic infiltrates in the meninges (Figure 3E). In
summary, histologic lesions were observed in the brain for up to 4
mo p.i. in mice with and without previous clinical disease,
suggesting that inflammation in the brain does not necessarily
cause clinical disease. Furthermore, these results provide evidence
for an immune response in the brains of mice in the face of viral
persistence.
Immunosuppression results in viral recrudescence
Since we observed inflammation in the brains of mice with
persisting WNV, we hypothesized that generalized immunosup-
pression after the establishment of viral persistence would allow
viral replication (i.e. viral recrudescence). Thus, we treated WNV-
inoculated mice at 28 days p.i. with cyclophosphamide, which
transiently suppresses actively dividing lymphocytes [35], or with
vehicle alone [phosphate buffered saline (PBS)]. One group of
treated mice was sacrificed to examine tissues for persistent WNV,
and another group was monitored for clinical disease. Three mice
per treatment (cyclophosphamide and PBS) were sacrificed twelve
days after the last treatment, and six tissues (skin at the inoculation
site, spinal cord, brain, lymph nodes, spleen, and kidney) per
mouse were examined for WNV by virus isolation and RT-PCR.
Infectious WNV was isolated from three of three mice (two to five
tissues per mouse) treated with cyclophosphamide and from none
of three mice treated with PBS (Table 3), which was statistically
different (P=0.05, Fisher’s exact test). Overall 9 of 18 tissues were
positive in the cyclophosphamide-treated group, which is signif-
icantly different than no positive tissues in the PBS-treated group
(P=0.0005, Fisher’s exact test). Detection of WNV RNA was not
different for the two treatment groups with 8 of 18 tissues (44%)
positive for both groups (Table 3). No disease was observed in the
remaining mice for at least 3 mo p.i. (data not shown), suggesting
that the immunosuppression was too transient for disease to occur
and/or the presence of WNV-specific antibody (Figure 2)
prevented disease. Furthermore, these results support our findings
that WNV persists as fully infectious virus at 1 mo p.i. (Table 1).
Discussion
In this study, we have demonstrated that WNV persists in the
CNS and peripheral tissues of mice for up to 6 mo p.i..
Furthermore, this persistence was observed in the CNS of mice
that did not exhibit disease during acute infection (i.e. subclinical
infection), which is consistent with our previous results that
neuroinvasion occurs in mice with subclinical infection [31]. The
frequency and levels of WNV persistence was tissue dependent.
WNV persisted most frequently as infectious virus in the skin and
as RNA in the skin, spinal cord, and brain. WNV persistence was
relatively frequent in lymphoid tissues, was uncommon in the
kidney, and rare in the heart. In addition, WNV persistence
occurred in the face of a strong antibody response and active
inflammation, and upon transient immunosuppression, the virus
recrudesced.
Persistence of WNV in the CNS was previously reported in
immunocompetent animals, but our results differ in the duration
of viral persistence and disease status of the animals. WNV persists
as infectious virus in brains of hamsters for up to 53 days [36] and
brains and spinal cords of macaques for up to 6 months [28]. Both
of these studies examined animals that were convalescent, and in
the macaque study, WNV was inoculated intracranially, which
may have affected persistence of WNV in the CNS. In contrast, we
observed infectious WNV for up to 4 months in the brain and
spinal cord after a peripheral inoculation (compared to approx-
Figure 1. Persistence and levels of WNV RNA varies for different tissues. Adult, female B6 mice were inoculated s.c. with diluent alone
(mock) or 10
3 PFU of WNV in the left rear footpad, and tissues were harvested from 8 to 9 WNV-inoculated mice and one mock-inoculated mouse at
various times p.i.. Levels of WNV genome copies per mg of GAPDH RNA were determined by real-time RT-PCR in (A) skin-inoculation site (left rear
footpad), (B) skin-distal sites (right rear footpad and both front footpads), (C) spinal cord, (D) brain, (E) lymph nodes (both popliteal and inguinal
lymph nodes), (F) spleen, (G) kidney, and (H) heart. Axis titles are the same for A–H. Each data point represents an individual animal, and the
horizontal solid line is the geometric mean. Data points on the x-axis are negative. Data for mock-inoculated mice were negative for WNV RNA at
each time point and are not shown on the graphs. Similar results were obtained in three independent studies performed at 1 mo p.i. (n=8 to 10) and
two independent studies performed at 2 mo p.i. (n=4 or 8).
doi:10.1371/journal.pone.0010649.g001
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mice with subclinical infection. In house sparrows, WNV RNA
persists in the brain for up to 30 days [30] whereas we observed
WNV RNA in the brains and spinal cords of mice for up to 3 and
6 months, respectively. Furthermore, we observed histologic
lesions in the brains of mice for up to 4 months, which to our
knowledge is the only report of brain pathology past the acute
phase of West Nile disease in any animal model. In summary, we
Figure 2. Mice maintain a robust antibody response during WNV persistence. Adult, female B6 mice were inoculated s.c. with diluent alone
(mock) or 10
3 PFU of WNV in the left rear footpad, and sera were harvested by serial tail bleeds or at time of sacrifice (Table S1 for details). Sera were
tested for WNV-specific antibodies by (A and B) MIA for anti-WNV E, (C and D) MIA for anti-WNV NS5, and (E) PRNT with 90% endpoint titers. Axis
titles are the same for A–D. The number of mice tested at each time point in A, C and E are placed above the whisker-box plots. In B and D, the same
mice (n=15) were bled at each time point, the results for an individual mouse over time is represented by a solid line, and the number of mice
positive at each time point is listed at the top of the graphs. The horizontal, dotted lines correspond to the LOD, and data points below the dotted
line are negative. Data for mock-inoculated mice were negative for WNV-specific antibodies in all assays and are not shown on the graphs.
doi:10.1371/journal.pone.0010649.g002
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persistence in the CNS of mice after peripheral inoculation
compared to hamsters [36] and house sparrows [30], and unlike
the macaques [28] and hamsters [36], the mice had subclinical
WNV infections.
Persistence of WNV in skin has been examined in only one
other published report, which studied persistence in house
sparrows. WNV RNA persisted in the skin of 10 out of 13 house
sparrows for 30 days, but infectious virus was not detected in the
skin using plaque assays [30]. In contrast, we observed WNV RNA
Figure 3. Histopathologic changes persist in the brains of mice during WNV persistence. Adult, female B6 mice were inoculated s.c. with
diluent alone (mock) or 10
3 PFU of WNV in the left rear footpad, and brains were harvested for histopathology from 8 WNV-inoculated mice and one
mock-inoculated mouse at 1, 2, 4, 6 and 9 mo p.i.. Representative photomicrographs of brains are shown at (A and B) 1 mo p.i. in the thalamus, (C
and D) 2 mo p.i. in the brainstem, and (E and F) 4 mo p.i. in the midbrain for WNV-inoculated mice (left panels) and mock-inoculated mice (right
panels). Black arrows point to areas of inflammation. Sections were stained with hematoxylin and eosin, and photomicrographs are shown at a
magnification of 2006(A, B, C, D, and F) and 4006(E).
doi:10.1371/journal.pone.0010649.g003
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respectively. Our ability to detect infectious virus may be due to
the use of the more sensitive co-culturing technique to isolate virus.
Furthermore, we detected WNV RNA in the skin for up to 4
months p.i., three months longer than was observed in house
sparrows. The longer duration may be due to greater initial viral
infection or different cell targets in the skin of mice compared to
house sparrows. Alternatively, the footpad is thick skin, which is
richly innervated and has a high density of mechanoreceptors, and
it may support greater viral persistence than thin skin on other
areas of the body. In addition, our results demonstrate that WNV
persistence is less frequent in skin distal from the inoculation site. It
is possible that dissection of the footpad ensured that we obtained
the inoculation site, which would be more difficult to identify on
the breast skin of a house sparrow [30].
Persistence of WNV in other peripheral tissues has been
documented in several animal species. Hamsters inoculated with
NY99 strain of WNV have persistent viruria for up to 52 days in
60% of the animals [29]. Although we did not examine urine in
our studies, it is unlikely that we would have observed frequent
viruria since only 25% of mice were positive for WNV RNA in
their kidneys through 60 days. In another study, Tesh et al. [37]
used an attenuated, hamster-adapted strain of WNV and observed
persistence of infectious virus in kidneys and urine for up to 247
days. Unlike our observations in mice, WNV infrequently persists
in spleens of hamsters [29,37]. In macaques, infectious WNV was
observed in kidneys, spleens and lymph nodes for up to 161 days
after immunosuppression with cyclophosphamide [28]. In wild
bird species, WNV RNA is detected in kidneys and hearts more
frequently at 30 days [30] and in kidneys at 6 weeks [38] than we
observed in mice; however, WNV persistence in spleens was
similar for mice and birds [30,38]. In summary, the frequency,
duration, and tissue location of WNV persistence are species
dependent. This dependence is most likely due to differences in the
host’s immune response, the severity of disease, initial viral loads,
tissue tropism, and cell targets.
Other factors may contribute to the differences observed in
persistence between various animal models, including viral strain,
viral dose, and route of inoculation. In our study and the house
sparrow study [30], 10
3 PFU of WNV was inoculated subcutane-
ously. In the hamster study [36], 10
4 PFU of WNV was inoculated
intraperitoneally. All three studies used strains of WNV belonging
to the NY99 genotype; however, our virus was derived from an
infectious clone and was likely more homogenous. In the macaque
study [28], ten strains of WNV were inoculated intracranially or
subcutaneously at 10
6 to10
7 suckling mouse lethal dose-50. These
strains were isolated over 30 years ago and have varied passage
history; therefore, they are likely very divergent from the NY99
genotype of WNV.
Persistence of flaviviruses also occurs in human patients
recovering from neuroinvasive disease (reviewed in [27]). In a
recent longitudinal study of convalescing humans, 20% of the
patients had detectable WNV RNA in their urine for 1.6 to 6.7
years after disease onset [19]. The duration of WNV persistence is
much longer than what has been observed in other animals or in
our studies of mice, and the long duration is likely influenced by
the initial disease severity of these patients, who were hospitalized
with neuroinvasive disease. In our study, mice with neuroinvasive
disease were euthanized during acute illness (7–14 days p.i.). Other
evidence of persistence in humans is the long duration of IgM,
which suggests that virus and/or viral antigen is persisting. Patients
with confirmed West Nile encephalitis have persistent serum IgM
against WNV for up to 16 months [23]; patients with West Nile
encephalitis [24] and Japanese encephalitis [25,26], a related
flavivirus, have persistent virus-specific IgM in their cerebrospinal
fluid for up to 5 to 6 months, suggesting that flaviviruses can persist
in the CNS of convalescing patients.
WNV also persists in humans after mild febrile illness or
subclinical infections. In a longitudinal study of WNV-positive blood
donors, 3% of the donors had detectable WNV RNA in blood
between 40 and 104 days after their index donation, using a very
sensitivetranscription-mediated amplification technique [20]. Prince
et al. [22] followed up WNV-positive blood donors, and serum IgM
against WNV persisted for up to 1 year, suggesting that virus and/or
antigen is persisting in these donors. The population of WNV-
positive blood donors is representative of the general population
infected with WNV in nature (80% subclinical infections, 20% West
Nile fever, and ,1% neuroinvasive disease) [22,39]. Thus, as
Table 3. Treatment of mice with cyclophosphamide resulted in recrudescence of WNV.
Infectious Virus (WNV RNA) in tissue
Mouse ID Inoculum Treatment on 28 and 33 days p.i. Skin–inoculation site
1 Spinal Cord Brain Lymph nodes
2 Spleen Kidney
2 Mock Cyclophosphamide 2 (2) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2)
9 WNV Cyclophosphamide + (+) + (+) 2 (2) 2 (2) 2 (2) 2 (2)
10 WNV Cyclophosphamide 2 (+) + (+) + (+) 2 (2) 2 (2) 2 (2)
12 WNV Cyclophosphamide + (+) + (+) + (+) + (2) 2 (2) + (2)
25 WNV PBS 2 (+) 2 (+) 2 (2) 2 (+) 2 (+) 2 (2)
26 WNV PBS 2 (+) 2 (+) 2 (2) 2 (+) 2 (2) 2 (2)
27 WNV PBS 2 (+) 2 (2) 2 (2) 2 (2) 2 (2) 2 (2)
2 negative, + positive.
1Skin at the inoculation site consisted of the left rear footpad.
2Lymph nodes consisted of both popliteal and both inguinal lymph nodes.
Adult, female B6 mice were inoculated s.c. in the left rear footpad with diluent alone (mock) or with 10
3 PFU of WNV. Mice were treated with cyclophosphamide or PBS
on days 28 and 33. Mice were sacrificed on day 45 p.i., and WNV infection was confirmed in all WNV-inoculated mice by seroconversion. Six tissues (skin–inoculation site,
spinal cord, brain, lymph nodes, spleen, and kidney) per mouse were harvested for virus isolation and RT-PCR for WNV. Virus isolation was performed by co-culturing the
homogenized tissues on Vero cell monolayers. All samples were passed two more times onto fresh monolayers, and tissue culture supernatants from the third passage
were tested for the presence of WNV by RT-PCR. Mouse #12 and mouse #25 were sick during acute phase of disease (7 to 14 days p.i.). All other mice did not show any
clinical disease.
doi:10.1371/journal.pone.0010649.t003
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persistence occurs in humans with subclinical infections.
We observed WNV persistence in our mouse model in the face of
a robust antibody response and inflammation in the brain.
Transient immunosuppression with cyclophosphamide resulted in
viralrecrudescenceasevidencedbytheisolationofinfectiousWNV,
suggesting that without actively dividing lymphocytes, WNV can
replicate. Similar results were observed upon cyclophosphamide
treatment of macaques inoculated with WNV [28] and mice
inoculated with Japanese encephalitis virus [40]. These results
suggest that WNV is persisting as infectious virus for months after
infection. In addition, the variability of the antibody levels to WNV
NS5 in our mice suggests that persistent WNV replicates
periodically, produces non-structural proteins, and stimulates the
immune response. The presence of fully infectious virus during
persistence has clinical implications for humans who are persistently
infected with WNV and subsequently become immunosuppressed.
We propose that after the establishment of viral persistence, there
is a smoldering viral infection that the immune response keeps in
check, but clears very slowly. Final viral clearance likely depends on
the cell type infected with longer persistence in cells with slow
turnover or cells such as neurons that the body must protect from
damage. Viral persistence is likely greater in tissues with less
immune surveillance, such as the CNS, which is supported by the
more frequent persistence in the CNS of our mice. Even within the
nervous system, there may be differences in clearance. We observed
longer persistence in the spinal cord than in the brain, suggesting
different clearance mechanisms in these sites, such as was observed
with Sindbis virus [41]. The initial disease status also likely affects
WNV persistence due to differences in initial viral load and/or
influences on the early immune response. We observed a trend
toward greater WNV persistence in mice that survived clinical
disease, and persistence of virus and IgM in humans appears longer
in patients recovering from West Nile neuroinvasive disease [19,23]
than in blood donors with mild or inapparent disease [20] although
direct comparisons have not been made.
The persistence of WNV has implications for human health.
Transmission of WNV occurs with organ transplantation from
acutely infected donors [42] and may possibly occur with
persistently infected donor organs in combination with immuno-
suppression of the recipient. In addition, it is unknown if WNV
persistence contributes to the long term sequelae observed in
patients recovering from West Nile encephalitis and West Nile
fever [6–18]. There have been over 11,000 human cases of West
Nile neuroinvasive disease and estimates of over 300,000 cases of
West Nile fever and over 1.2 million humans with asymptomatic
infections of WNV in the United States through 2007 [5]. The
potential impact on this population is great. Future studies are
needed to develop a model for long term sequelae and to further
our understanding of WNV persistence, including studies on
mechanisms of persistence and the immune response during viral
persistence.
Materials and Methods
Ethics statement
All studies were approved by the Institutional Animal Care and
Use Committee of the Wadsworth Center under protocol #06-
377 and followed criteria established by the National Institutes of
Health.
Cells and virus
African green monkey kidney cells (Vero; ATCC #CCL-81)
and baby hamster kidney cells (BHK-21; ATCC #CCL-10) were
maintained in supplemented medium [minimum essential medium
(GibcoH Invitrogen, Carlsbad, CA) with 5% fetal bovine serum,
2 mM L-glutamine, 1.5 g/L sodium bicarbonate, 100 U/ml of
penicillin, and 100 mg/ml of streptomycin]. Cells were incubated
at 37uC, 5% CO2.WNV was produced from a full-length cDNA
clone of a 2000 New York strain (NY99 genotype) by
electroporation of BHK-21 cells with in vitro transcribed RNA as
previously described [43]. Viral titers of stocks were determined by
plaque assay on Vero cells.
Mouse studies
Five-week-old, female B6 mice were purchased from Taconic
(Germantown, NY), acclimatized for at least 1 week in the BSL-3
animal facility, and given food and water ad libitum. For virus
inoculation, six- to seven-week-old B6 mice were inoculated s.c. in
the left rear footpad as previously described [31] with diluent alone
(mock) or 10
3 PFU of WNV. The diluent for viral inocula was
endotoxin-free PBS (tissue culture grade; Invitrogen) with 1% fetal
bovine serum. In this B6 mouse model, the lethal dose-50% is
greater than 10
5 PFU (Bernard, unpublished data), and the
infectious dose-50% is 1 PFU [44]. After inoculation, all mice
were observed for clinical disease daily for the entire study. All
mice were weighed daily for at least 14 days p.i., three times per
week for the 3rd and 4th weeks p.i., and once per week for the
remainder of the study. Clinical signs included ruffled fur,
hunching, ataxia, and weakness. A mouse was considered to have
clinical West Nile disease if at least one of the following criteria was
met: 1) $10% weight loss; 2) clinical signs for at least two days.
Mice that exhibited severe disease were euthanized. No clinical
signs or weight loss were observed in mock-inoculated mice. At 1
mo p.i., all WNV-inoculated mice were seropositive for WNV.
Viral persistence study
A study to assess viral persistence in mice was performed using a
single cohort of B6 mice. Mice were inoculated with diluent alone
(n=8) or WNV (n=82) and monitored as described above. One
mock-inoculated mouse and eight to nine WNV-inoculated mice
were sacrificed at 1, 2, 3, 4, 6, and 9 mo p.i., and tissues were
harvested (see below). At all time points except 4 mo p.i., one
mouse was sacrificed that was previously sick during the acute
phase of disease (7 to 14 days p.i.), and the other seven to eight
WNV-inoculated mice had subclinical infection (i.e. no clinical
signs of disease). All mice were bled at 1 mo p.i., and infection was
confirmed in all WNV-inoculated mice by seroconversion, using
an ELISA for WNV as previously described [31]. Mice that were
not sacrificed were serially bled for serologic assays at 2, 4, 6, 9,
and 13 mo p.i.. At 16 mo p.i., the remaining 15 WNV-inoculated
and 2 mock-inoculated mice were sacrificed, and tissues were
harvested (see below). Table S1 summarizes the study design.
Tissue harvesting and processing
The following tissues were harvested at each time point: serum,
skin–inoculation site (left rear footpad), skin–distal site (right rear
and front footpads pooled together), lymph nodes (both popliteal
and both inguinal lymph nodes pooled together), spleen, heart,
kidney, spinal cord, and brain. The brain was cut on the median
plane; one-half was processed for virus isolation, and the other half
was processed for histopathology (see below). Tissues were
processed as previously described except that tissues were not
frozen [31]. Briefly, tissues were harvested and weighed, and BA-1
diluent (M199, 1% bovine serum albumin, 0.05 M Tris pH 7.6,
0.35 g/L sodium bicarbonate, 100 U/ml penicillin, 100 mg/ml
streptomycin, 1 mg/ml fungizone) was added to make a 20%
homogenate for all CNS tissues and a 10% homogenate for all
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added.
Virus isolation
On the same day as tissue harvesting, the homogenized tissues
were immediately processed for virus isolation as follows (see flow
chart inFigureS1).Tissuehomogenate(100 ml)wasinoculatedonto
Vero cells in a 6-well plate (‘‘pass 1’’). Cultures were incubated at
37uC, 5% CO2 for 4 to 5 days and were observed daily for CPE. All
samples were passed at least one more time (‘‘pass 2’’) to ensure that
any CPE was not due to toxicity caused by the sample. After the
second pass, all CPE-negative samples were passed one more time
(‘‘pass 3’’). The second and third passes were done by inoculating
500 mlcellculturesupernatantontoVerocellsin6-wellplates.Real-
time RT-PCR assays (see below) were performed on all CPE-
positive samples to confirm the presence of WNV, and assays for
both WNV E and NS5 genes were positive. In order to detect slow
growing or non-cytopathic virus, real-time RT-PCR assays that
targeted both WNV E and NS5 genes were performed on all
samples that were negative for CPE on ‘‘pass 3’’. The few ‘‘pass 3’’
samples that were CPE-negative and WNV RNA-positive were
passed a fourth time on Vero cells.
RNA extraction
On the same day as tissue harvesting, tissue homogenate (50 ml)
was mixed with 350 ml of RLT lysis buffer (Qiagen, Valencia, CA)
and placed at 280uC until RNA extraction was performed (Figure
S1). RNA was extracted from tissues and cell culture supernatants,
using RNeasy Mini Kit per the manufacture’s protocol (Qiagen).
Extreme care was taken to avoid contamination and false positive
results. For example, RNA extractions of CPE-positive cultures
were performed on different days than extractions of tissues or
CPE-negative cultures. No contamination was observed for tissues
from mock-inoculated animals or for cell culture supernatants that
were inoculated with tissues from mock-inoculated mice. In
addition, reagent controls were run with every RNA extraction,
and no contamination was observed.
Real-time RT-PCR
WNV RNA was quantified using real-time RT-PCR assays for
WNV as previously described [45,46] with the following details.
Two different primer/probe sets for WNV were used in two
separate reactions, using TaqManH One-Step RT-PCR (Applied
Biosystems, Inc., Foster City, CA). The TaqManH probes
contained a 59 6-carboxyfluorescein (FAM) reporter and a 39 6-
carboxy-N,N,N’,N’-tetramethylrhodamine (TAMRA) quencher.
One primer/probe set targeted WNV E (forward primer 59-TCA-
GCGATCTCTCCACCAAAG-39, reverse primer 59-GGGTCA-
GCACGTTTGTCATTG-39, and probe 59-FAM-TGCCCGAC-
CATGGGAGAAGCTC-TAMRA-39). Another primer/probe set
targeted WNV NS5 (forward primer 59-GCTCCGCTGTC-
CCTGTGA-39, reverse primer 59-CACTCTCCTCCTGCATG-
GATG-39, and probe 59-FAM-TGGGTCCCTACCGGAA-
GAACCACGT-TAMRA-39). A sample was considered positive
if the cycle threshold was $38. Some of the tissues were only
positive for the WNV E gene; this was not unexpected since the
assay for the E gene is more sensitive than the assay for the NS5
gene [45,46]. RNA standards were in vitro transcribed from WNV
cDNA and quantified as WNV genome copies, and 10-fold
dilutions from 50 to 500,000 WNV genome copies were used as a
standard curve. For RNA extracted from tissues, a third reaction
was performed using a primer/probe set for a housekeeping gene
(TaqManH Rodent GAPDH, Applied Biosystems, Inc.). Rodent
GAPDH standards (Applied Biosystems, Inc.) were used at 0.005
to 50 pg in 10-fold dilutions. Values for GAPDH and for WNV
genome copies, using results for the primer-probe set targeting the
E gene, were calculated by linear regression of the standard curves
(Applied Biosystems, Inc.).
Microsphere immunoassay for antibody to WNV
Sera collected from mice (Table S1) were analyzed for WNV-
specific antibody by fluorescent MIA at a dilution of 1:100 as
previously described [34]. Briefly, microspheres (Luminex Corpo-
ration, Austin, TX) were coated with a recombinant WNV E
antigen or a recombinant WNV NS5 antigen [34,47]. Serum
samples were diluted and incubated with the WNV E and WNV
NS5 microspheres at 37uC for 30 minutes in darkness. After
extensive washing, secondary polyvalent goat anti-mouse immu-
noglobulins (IgG, IgA, and IgM) conjugated to red-phycoerythrin
were added to the samples, incubated for 30 minutes, and washed
twice. The fluorescence intensity of the microspheres and MFI of
the secondary antibody bound to the microspheres were analyzed
with a Luminex 100 instrument (Luminex Corporation). Serum
samples with MFI values greater than the cutoff were considered
positive. Cutoff values were determined for each lot of beads and
were based on the average MFI of serum samples from mock-
inoculated mice plus three standard deviations (MicrosoftHOffice
Excel, Microsoft Corporation, Seattle, WA). Cutoff values were: 1)
MFIs of 20 and 860 for WNV E and WNV NS5 assays,
respectively, for serum samples from 1, 2, 4, 6, 9 and 13 mo p.i.; 2)
MFIs of 20 and 370 for WNV E and WNV NS5 assays,
respectively, for serum samples from 16 mo p.i.. The data are
shown as whisker-box plots with high and low values represented
at the ends of the bars (GraphPad, San Diego, CA). The box
represents the middle two quartiles (25th to 75th percentile) with
the median represented as the horizontal line inside the box. A
two-sided paired t test was used to analyze MFI data in the same
mice at different time points (GraphPad).
Virus neutralization assays
Sera collected from mice were also analyzed for neutralizing
antibodyusingaPRNT.Duetolimitationsinsamplesizefrommice
that were bled from a peripheral vein, PRNTs were performed on
sera from euthanized mice (1, 2, 4, 6, 9 and 16 mo p.i.) and from
mice bled at 13 mo p.i. At 13 mo p.i., mice were bled two times one
week apart, and the two serum samples were pooled together for
each individual mouse, resulting in sufficient volume for the assay.
All sera were heat-inactivated at 56uC for 1 hour prior to testing.
Two-fold dilutions of the serum samples, starting at a final dilution
of 1:20, were incubated overnight at 4uC with 200 PFU of WNV.
The virus-serum samples and appropriate controls were added to
Vero cell monolayers in 6-well plates and incubated for 1 hour at
37uC, 5% CO2. Primary overlay (0.6% oxoid agar in supplemented
medium) was added to each well, and plates were incubated for 2
days at 37uC, 5% CO2. On day 2, secondary overlay (0.6% oxoid
agar in supplemented medium plus 0.33% Neutral Red) was added
toeachwell.Plateswereincubatedovernightat37uC,5%CO2,an d
plaques were counted. End point titers were determined for the
highest dilutions that inhibited 90% of viral plaques (PRNT90)a n d
50% of viral plaques (PRNT50). Titers of ,1:20 were considered
negative. The data are shown as whisker-box plots with high and
low values represented at the ends of the bars (GraphPad). The box
represents the middle twoquartiles (25th to 75th percentile) with the
median represented as the horizontal line inside the box.
Histopathology
Brains were harvested from mice that were sacrificed in the
persistence study and processed for histology as follows. The brains
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formalin. After fixation for 1 week, tissues were paraffin
embedded, and 6 mm sections were cut on a microtome (Leica
Microsystems, Inc., Bannockburn, IL). Each section from a block
contained representative areas of all brain regions. Slides were
stained with hematoxylin and eosin. A board-certified veterinary
pathologist (M.J.B) evaluated the brains (one slide per mouse) for
the presence of histologic lesions, using mock-inoculated mice
from each time point as comparisons. No histologic lesions were
observed in mock-inoculated mice.
Cyclophosphamide treatment
B6 mice were inoculated s.c. with diluent alone (n=8) or with
10
3 PFU of WNV (n=22) and monitored as described above. The
treatment regimen for cyclophosphamide was based on a
previously published protocol [48]. On day 28 p.i., surviving mice
were divided into two treatment groups. Group 1 was treated
intraperitoneally with 5 mg cyclophosphamide (approximately
200 mg/kg, Sigma-Aldrich, St. Louis, MO) in endotoxin-free PBS
and consisted of four mock-inoculated and ten WNV-inoculated
mice. Group 2 was treated intraperitoneally with vehicle
(endotoxin-free PBS) and consisted of four mock-inoculated and
nine WNV-inoculated mice. A second treatment was administered
on day 33 p.i.. Seventeen days after the first treatment, three
WNV-inoculated mice from each treatment group and one mock-
inoculated mouse from group 1 were sacrificed, and the following
tissues were harvested: serum, skin–inoculation site (left rear
footpad), lymph nodes (both popliteal and both inguinal lymph
nodes pooled together), spleen, kidney, spinal cord, and brain.
Tissues were processed for virus isolation and real-time RT-PCR
assays as described above. A one-sided Fisher’s exact test was used
to compare the number of positive mice and the number of
positive tissues in each treatment group (GraphPad). The
remaining mice were monitored for clinical disease until the end
of the study at 14 weeks p.i.
Supporting Information
Figure S1 Experimental design. Flowchart depicting tissue
processing for virus isolation and RNA extraction.
Found at: doi:10.1371/journal.pone.0010649.s001 (0.23 MB TIF)
Table S1 Study design for WNV persistence in mice. The table
provides the numbers of mice bled or sacrificed at each time point,
including the number of mice with and without clinical disease
during acute phase of disease (7 to 14 days p.i.).
Found at: doi:10.1371/journal.pone.0010649.s002 (0.04 MB
DOC)
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